The magazine ranked companies worldwide based on their ‘Innovation Premium’, which Forbes says is the difference between the current market capitalization and a net present value (NPV) of company income from existing businesses. The difference between the two values equates to the bonus given by investors who identify the firm as being able to grow and profit in the future.
Alexion’s Innovation Premium is 72.3%, second only to software company Salesforce.com. This is the second year running that Alexion has been ranked number 2 on the list.
Alexion Pharmaceuticals are a platinum sponsor at this year’s World Orphan Drug Congress Europe 2013, Geneva, 14-15 November 2013. Martin Mackay, EVP and Global Head of R&D at Alexion, will be giving a keynote presentation on ‘Ultra-orphan therapies – broad skills for small populations’. Download the brochure here >